Objectives: Response to epidermal growth factor receptor inhibitors is poorer among stage IV colorectal cancer (CRC) patients with KRAS mutations; thus KRAS testing is recommended before treatment. KRAS testing was collected by Surveillance, Epidemiology, and End Results (SEER) registries for 2010 CRC cases, and our goal was to provide the first population-based estimates of testing in the United States.
A pproximately 136,830 new cases of invasive colorectal cancer (CRC) were diagnosed in 2014 in the United States. 1 It is the third most commonly diagnosed cancer and third leading cause of cancer death in the United States. 1 Twenty percent of CRC cases are stage IV at diagnosis. 2 Antiepidermal growth factor receptor (anti-EGFR) drugs have proven effective at slowing progression of stage IV CRC. [3] [4] [5] [6] However, studies have demonstrated that the presence of KRAS mutations, which occur in approximately 40% of stage IV patients, 7, 8 make response to anti-EGFR therapy less likely. [9] [10] [11] [12] [13] [14] [15] [16] In 2009, both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) published updated CRC treatment guidelines. 9, 17 NCCN recommends KRAS testing for all patients upon diagnosis of metastatic CRC, and that only those with tumors characterized by the wild-type KRAS gene should receive anti-EGFR therapy, whereas ASCO recommends KRAS testing in all patients for whom anti-EGFR therapy is being considered. 9, 17 Consequently, in 2010, KRAS was included as a sitespecific factor (SSF) to be collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program.
Although KRAS testing for stages I-III CRC is not recommended, it has been suggested that KRAS status can be used as a prognostic indicator in all stages. [18] [19] [20] Our objectives were to document the US population estimates of KRAS testing using data from the SEER Program for both stage IV and stages I-III CRC patients, as well as to determine factors associated with receipt of testing, including survival. In particular, geographic variation of KRAS testing was examined to highlight issues potentially related to differential diffusion, adherence, or access to KRAS testing.
MATERIALS AND METHODS

Data Source and Study Population
Cases of invasive CRC diagnosed in 2010 in any of the SEER 18 Registries: the states of California (including Los Angeles, San Francisco, San Jose, and Greater California Registries), Connecticut, Georgia (including Atlanta, Rural Georgia, and Greater Georgia Registries), Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah, as well as the metropolitan areas of Detroit and Seattle, were extracted using SEER*Stat (version 8.1.2). Cases were included in the analysis if they had diagnostic confirmation by positive histology and were of the histologic types included in the Colon & Rectal Cancer Collaborative Stage (CS) Schema v0204. 21 Cases were excluded if they had an American Joint Committee on Cancer (AJCC) seventh edition 22 stage equal to "not applicable" (n = 45) or "unknown" (n = 2093), if they were diagnosed on autopsy or death certificate only (n = 28), if they were not microscopically confirmed (n = 524), or if they had a histology of squamous cell neoplasms (n = 161) or cloacogenic carcinoma (n = 1). Furthermore, cases in the Alaska Natives registry (n = 65) were excluded because of extremely small numbers. Special access to CRC SSF 9 (KRAS testing) was granted by the National Cancer Institute. This study was granted human subject exemption status by the University of Iowa Institutional Review Board.
Variables
The primary outcome variable was receipt of KRAS testing. Testing was considered done if the SSF 9 variable had a value of "abnormal (mutated)" or "normal (wild type)"; otherwise KRAS testing was not considered to be done if coded as "test ordered, results not in chart," "not done," or "unknown." Results of KRAS testing were also examined.
Patient demographic variables included age, sex, race, marital status, health insurance, SEER registry, and metropolitan (metro)/urban versus nonmetro/rural county of residence. Clinical variables included tumor location (colon vs. rectum and left/rectum vs. right side), histology, grade, first versus subsequent primary cancer, and presence of other primary cancer(s). Treatment variables included primary site surgery and recommendation for, or receipt of, radiation therapy. The number of months survived postdiagnosis was also examined by stage and KRAS testing, with a maximum of 11 months of follow-up.
Statistical Analyses
Analyses were stratified by stage IV versus stages I-III. To address the effect of incomplete documentation and/or incomplete clinical workup on KRAS testing as recorded by the SEER registries, a missing category for variables with large numbers of missing values was included in analyses. Differences in characteristics between those with and without KRAS testing were assessed using w 2 tests. Multivariate logistic regression analyses were conducted to determine patient characteristics associated with KRAS testing, with all variables listed above (except AJCC T and N stage as they are main components in determining overall stage) considered for inclusion in the models. Variables that were not significant predictors (P > 0.10) of KRAS testing were removed in a manual backward selection process. Kaplan-Meier curves and log-rank tests were used to evaluate the association between KRAS testing and survival. All tests of statistical significance were 2-sided. Analyses were conducted using SAS software (version 9.3, SAS Institute, Cary, NC).
RESULTS
The study population included 6119 cases of stage IV and 24,232 cases of stages I-III CRC. Variables with missing case information included race (n = 229), insurance (n = 871), marital status (n = 1614), county of residence (n = 5), grade (n = 2761), T stage (n = 1512), and nodal status (n = 890). Table 1 summarizes KRAS values by stage and location (colon vs. rectum). The overall proportion of KRAS testing captured by SEER registries was 22.7% among stage IV cases and 5.3% among stages I-III cases. Of the 1390 stage IV cases who received KRAS testing, 58% were classified as wild type and 42% were classified as mutated. Among the 1277 cases of stages I-III who received testing, 64% were classified as wild type and 36% were classified as mutated. There was no significant difference in KRAS testing or mutation rates between colon and rectum sites for stage IV or I-III (results not shown).
Stage IV Cases
Among those with stage IV CRC, for whom KRAS testing is recommended either upon diagnosis or before initiating anti-EGFR therapy, the following demographic characteristics were associated with higher proportions of KRAS testing ( Table 2) : younger age, white, other, or missing race (marginal association, P = 0.06), being married, and living in an urban/metro area. Substantial variation between registries was detected, ranging from 15% receiving KRAS testing in Louisiana to 39% in New Mexico. The following tumor and treatment characteristics were also associated with higher proportions of KRAS testing (Table 3) : adenoma/adenocarcinoma and cystic/mucinous/serous histology, nonmissing grade, more advanced T stage, nodal involvement, single primary cancer, no prior cancer history, and primary site surgery. Cases with "not otherwise specified" (NOS), "other," or "unknown" tumor characteristics had a lower proportion of KRAS testing compared with cases with specific information.
In multivariate analyses (Table 4) , younger age, residing in New Mexico, Seattle, or Hawaii, and having primary site surgery were associated with greater odds of receiving KRAS testing. Being single (never married) or missing marital status, having histology of epithelial neoplasm NOS or other/unspecified, missing grade information, receipt or recommendation for radiation, and residing in Louisiana or in nonmetro areas were associated with lower odds of receiving KRAS testing.
Stage I-III Cases
Among those with stages I-III, for whom KRAS testing is not explicitly recommended, the following demographic characteristics were associated with higher proportions of KRAS testing ( the highest proportions of testing (11.3% and 10.5%, respectively), whereas those in Louisiana or Iowa had the lowest (3.1% and 1.7%, respectively). The following tumor and treatment characteristics were associated with higher receipt of KRAS testing (Table 3) : tumors with histology of cystic/ mucinous/serous or other/unspecified, poor to undifferentiated grade, higher stage, more advanced T and N stages, no prior cancer, primary site surgery, and radiation therapy. In multivariate analyses (Table 4) , younger age, being single (never married) or divorced, missing race cystic/mucinous/serous histology, poor to undifferentiated tumor grade, and higher stage (II or III) were associated with greater odds of receiving KRAS testing, whereas missing marital status, living in a nonmetro area, missing grade, and being uninsured or missing insurance information were associated with lower odds of KRAS testing. In addition, those residing in Seattle, New Mexico, Kentucky, or Georgia had greater odds of receiving KRAS testing, whereas those in Iowa, and New Jersey had lower odds of receiving KRAS testing.
Survival Time
Survival months by KRAS testing status and stage (IV vs. I-III) are displayed in Table 5 . Those with stage IV CRC who survived the longest had higher receipt of testing compared with those who survived a shorter time. Thirty percent of stage IV cases surviving at least 11 months received KRAS testing, compared with 14% of stage IV cases surviving <1 month. Fig. 1 shows the Kaplan-Meier curves for stage IV cases who received KRAS testing compared with those who did not. A log-rank test indicated that the curves were significantly different (P < 0.0001). Among stage IV cases who received KRAS testing, there was no significant difference in survival by The relationship between survival months and receipt of KRAS testing was much less pronounced among stages I-III cases (Table 5 ). Four percent of those surviving <1 month received KRAS testing compared with 6% of those surviving at least 11 months, but proportions of testing increased and decreased between those time points. Supplementary Figure 2 (Supplemental Digital Content, http://links.lww.com/AJCO/ A87) shows the Kaplan-Meier curves for stage I-III cases who received KRAS testing compared with those who did not. A log-rank test indicated that the curves were significantly different (P < 0.0001).
DISCUSSION
Despite the recommendation by NCCN that all patients diagnosed with stage IV CRC undergo KRAS testing for treatment planning purposes, SEER data indicate that only 23% of stage IV cases received testing in 2010, and that testing rates vary substantially by geographic region and patient characteristics. Our estimate is similar to the 29% of cases found to be tested for KRAS mutations within 90 days of diagnosis of metastatic CRC in 7 Health Maintenance Organizations across the United States in 2009. 23 The proportion tested also falls within the range found on medical record review of 3820 patients seen by participating physicians for stage IV CRC in 2010 across 14 countries in Europe, Latin America, and Asia (40%, 27%, and 12%, respectively). 24 A variety of factors may explain the low proportion and geographic variation of KRAS testing in our national, populationbased estimates.
First, the recommendation by ASCO differs from that of NCCN in that KRAS testing is recommended for those who are being considered for anti-EGFR therapy, not all stage IV CRC patients. 9, 17 For patients diagnosed with very advanced disease with short life expectancies, the oncologist and/or patient may decide to forego treatment with chemotherapy, hence eliminating the need for KRAS testing. 9 A recent nationwide study of stage IV CRC patients who received chemotherapy between January 2004 and March 2011 found that 26% of these patients had received anti-EGFR therapy, with its use falling by 18% after the US Food and Drug Administration limited anti-EGFR use to patients with wild-type KRAS expression. 25 Although a benefit has been established for anti-EGFR treatment in patients with wild-type KRAS, response rates to anti-EGFR therapy can be modest and even nonexistent in certain patients, 13 perhaps causing some providers to be reluctant to offer anti-EGFR therapy/KRAS testing. Furthermore, some clinicians may be more comfortable with other recommended, more established chemotherapy regimens. Second, SEER only collects incident cases of cancer, so it is possible that the rate of KRAS testing among those initially diagnosed with stage IV would be lower than would be anticipated among all metastatic cases. Those initially diagnosed with earlier-stage cancer that later progressed to metastatic' disease may have been under more frequent surveillance. Therefore, their metastasis may have been detected at an earlier and potentially more treatable point, making them more likely to receive anti-EGFR therapy and consequently be KRAS tested. Conversely, those who were initially diagnosed as stage IV may have had more advanced disease and less interest in pursuing treatment with chemotherapy. There were a number of cases with stage or site information categorized in an "NOS"-related category, which suggests that they may not have undergone thorough staging procedures because of their general health. A recent nationwide study of patients with metastatic cancer at diagnosis found that close to 16% of both colon and rectum cases received no form of anticancer therapy. 26 Another recent study that examined treatment in Medicare patients (aged 66 y or older) with stage IV CRC at diagnosis found that only 45% received systemic chemotherapy. 27 There is wide variation in KRAS testing in stage IV patients by SEER registry. The fact that the patterns of KRAS testing within registries differed somewhat between stages I-III and stage IV suggests that the variation between registries is not simply due to differences in data capture. Louisiana, Iowa, and Kentucky had low KRAS testing in stage IV cases. These states contain large, rural areas located long distances from academic medical centers. It is possible that KRAS testing and use of anti-EGFR therapy in these states is most commonly done in larger medical centers, but has not yet diffused out into smaller community hospitals and practices in which CRC cancer cases are frequently treated. This was supported by the finding that patients residing in urban areas had higher rates of KRAS testing after controlling for other key factors. Alternatively, it could be that providers in states such as Louisiana, Iowa, and Kentucky conduct KRAS testing as frequently as providers in other states, but more frequently send their specimens to out-of-state private pathology laboratories, thus impeding the ability of cancer registrars to abstract the information. Future studies will focus on validating the KRAS SSF values to determine whether instances of KRAS testing were missed. In addition, the Iowa and Louisiana registries will be classifying the treating facilities into academic medical centers versus community hospitals with accredited cancer programs versus community hospitals with no accredited cancer program to determine whether KRAS testing patterns are substantially different by type of treatment facility.
A missing category was included in the analyses of variables with missing information (race, insurance, marital status, grade, AJCC T and N stage) to address the effect of incomplete documentation and/or clinical workup on KRAS testing as recorded by the registries. In multivariate analysis, missing marital status and grade were associated with nonreceipt of KRAS testing in stage IV cases, whereas missing marital status, grade, and insurance were associated with no KRAS testing for stages I-III. Although this may be indicative of incomplete documentation, especially for stage I-III cases in which both missing marital status and insurance were significant, missing grade information may also indicate an incomplete clinical workup, perhaps because of patient preference for limited/no workup or treatment, and/or advanced disease/comorbidities making treatment unfeasible. Interestingly, for stage I-III cases, having missing race information was associated with KRAS testing. Although not significant, the black and other stage I-III race categories had lower odds of testing, suggesting that many of those missing race information were white.
After controlling for registry site, it appears that several patient characteristics are important in the decision to order KRAS testing. Younger patients, for example, underwent KRAS testing at a more frequent rate. This may be due to better general health and longer life expectancy or due to seeking treatment at medical centers where KRAS testing is more frequently performed. In the aforementioned study of Health Maintenance Organization stage IV CRC cases, nonreceipt of chemotherapy, older age, higher Charlson comorbidity index score, and mortality within 6 months of stage IV CRC diagnosis were all associated with not receiving KRAS testing. 23 Interestingly, in this current analysis, having health insurance was not associated with KRAS testing among stage IV patients, but was among stages I-III patients.
Those with stage IV disease who were single (never married) had lower odds of KRAS testing, which suggests that having a spouse or other family support was important in a patient or provider's decision to recommend testing and anti-EGFR therapy. Conversely, being divorced or single (never married) was actually associated with higher odds of having KRAS testing among patients with stage I-III disease, which suggests a different decision-making process among patients and providers when dealing with earlier-stage versus laterstage disease. Stage was clearly an important consideration in the nonmetastatic population, given that stage III patients had >3 times greater odds of KRAS testing compared with stage I patients, and stage II patients had twice the odds of KRAS testing compared with stage I patients. Although KRAS testing is not recommended for earlier-stage cancers, studies suggest KRAS mutations may have prognostic significance, and thus may be used for reasons beyond anti-EGFR therapy. 28 A recent CRC chemotherapy trial of stage III cases found that KRAS mutations were independently associated with disease-free survival, suggesting that KRAS testing should be expanded to stage III CRC. 29 In addition, some patients might have clinically diagnosed metastatic CRC and therefore were KRAS tested, but were downstaged after more diagnostic procedures were performed.
In terms of survival, a clear advantage was demonstrated among those who received testing. As there was no significant survival difference detected between those with KRAS mutations and those with wild-type status, it appears that the survival advantage was more likely related to the selection of patients for KRAS testing rather than treatment with anti-EGFR therapy. Poor prognostic factors negatively associated with receipt of testing, including older age, more advanced T and N stage, and prior cancer, may have influenced the decision to forego testing at the time of diagnosis. In fact, >50% of stage IV CRC cases who had no KRAS testing died <3 months after diagnosis, compared with 30% who had KRAS testing, suggesting that those not receiving KRAS testing were generally in poorer health.
The survival advantage could also be related to those living longer having more of an opportunity to be tested. Anti-EGFR therapy may have only been considered after the patient failed other chemotherapeutic agents. Therefore, patients would have had to live long enough to fail 1 regimen and be considered for a second regimen involving anti-EGFR therapy in order to be tested. Although this approach is not totally consistent with NCCN guidelines for KRAS testing, it is in accordance with ASCO guidelines. 9, 17 Limitations of this study must be considered when interpreting results. SEER does not collect information about specific KRAS testing methods, and it is not possible to assess rates of false positives or negatives. However, our estimate of KRAS mutations occurring in 42% of stage IV patients is consistent with previously published estimates of approximately 40%. 7, 8 This analysis was based on a new variable collected for the first time in 2010. The primary source of information used by cancer registrars to collect information across all cancer cases is the hospital medical record. The primary source of KRAS testing information is the hospital pathology report. KRAS results are part of the College of American Pathologists (CAP) protocol, but reporting is optional, partly because this result is not always available when the pathology report is issued. 30 Thus, KRAS testing may not always be documented in the pathology report, or it may be added as an addendum at a later time, potentially after the report was abstracted by the cancer registrar. In addition, physician offices, or even hospitals, may send specimens to private out-of-state pathology laboratories for KRAS testing, and some of these laboratories may not be a case finding source for the registries. Thus, KRAS results not incorporated into the patient's hospital medical record could be missed by registries.
Furthermore, SEER only collects information related to first-course therapy. If anti-EGFR therapy was offered as a second-line option and KRAS testing was deferred until that point, it is possible the testing occurred outside the registry chart abstraction window. SEER also only captures cases who reside within SEER areas, but the current SEER 18 Registries cover 28% of the population, 31 and the cancer cases included in SEER are widely considered to be representative of the US cancer population. 32 Finally, SEER data do not capture patient or provider preferences or reasons for refusal of testing.
In conclusion, this is the first US study to provide both population estimates and patient characteristics associated with KRAS testing among CRC patients, and provides the oncology community with baseline testing rates for stage IV patients for whom targeted treatments are available. The results show that just over 1 in 5 stage IV CRC patients receives KRAS testing, and substantial variation exists by geographic region and patient characteristics. Somewhat surprisingly, it was also found that approximately 5% (and in certain geographic areas up to 10%) of nonmetastatic patients received KRAS testing despite it not being recommended in the guidelines. Our findings suggest the need to clarify KRAS testing protocols and improve the uptake of these guidelines across all geographic areas of the United States, as it is possible that testing and/or anti-EGFR therapy are not uniformly accessible to those who could benefit. The results can also guide the development of future studies to evaluate variations in KRAS testing and its impact on patient outcomes.
Our analyses also highlight the need for more complete reporting and standardization of data included in medical records and registries, as important clinical variables can only be analyzed when they are accurately documented and captured. Complete capture of KRAS testing information will provide an opportunity to evaluate therapy options and quality of care, and to assess survival outcomes. This could be facilitated by inclusion of KRAS testing in CAP protocols for all stage IV CRC cases. Given increased interest in tumor biomarkers and their impact on prognosis and prediction of cancer treatment response, it is highly likely that researchers will be interested in using KRAS and other similar prognostic and predictive factors in their analyses. It is anticipated that data capture and quality will improve with time and will allow researchers to assess the pattern of dissemination and diffusion in clinical practice of KRAS testing in different regions of the country.
